Alessandra Mandolesi

Alessandra Mandolesi

Auto-generated profile, based on publicly available information

Alessandra Mandolesi

Institute of Pathology, AO ospedali Riuniti-UNIVPM, Ancona, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
Mario ScartozziMario Scartozzi
Mario Scartozzi
IBItalo Bearzi
Italo Bearzi
AMAlessandra Mandolesi
Alessandra Mandolesi
CPChiara Pierantoni
Chiara Pierantoni
FLFotios Loupakis
Fotios Loupakis
SCStefano Cascinu
Stefano Cascinu
K-RAS wild type colorectal tumors show an improved response rate to anti-EGFR monoclonal antibodies. Nevertheless 70% to 40% of these patients still does not seem to benefit from this therapeutic approach. FISH EGFR GCN has been previously demonstrated to correlate with clinical outcome of colorectal cancer treated with anti-EGFR monoclonal antibodies. CISH also seemed able to provide accurate EGFR GCN information with the advantage of a simpler and reproducible technique involving immunohistochemistry and light microscopy. Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab. Patients with advanced K-RAS wild-type, colorectal cancer receiving irinotecan-cetuximab after failure of irinotecan-based chemotherapy were eligible. A cut-off value for EGFR GCN of 2.6 and 2.12 for FISH and CISH respectively was derived from ROC curve analysis. Forty-four patients were available for analysis. We observed a partial remission in 9 (60%) and 2 (9%) cases with a FISH EGFR GCN ≥ 2.6 and < 2.6 respectively (p = 0.002) and in 10 (36%) and 1 (6%) cases with a CISH EGFR GCN ≥ 2.12 and < 2.12 respectively (p = 0.03). Median TTP was 7.7 and 6.4 months in patients showing increased FISH and CISH EGFR GCN whereas it was 2.9 and 3.1 months in those with low FISH and CISH EGFR GCN (p = 0.04 and 0.02 respectively). FISH and CISH EGFR GCN may both represent effective tools for a further patients selection in K-RAS wild-type colorectal cancer treated with cetuximab.

10 April 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Mario ScartozziMario Scartozzi
Mario Scartozzi
RGRiccardo Giampieri
Riccardo Giampieri
EMElena Maccaroni
Elena Maccaroni
AMAlessandra Mandolesi
Alessandra Mandolesi
SBSimona Biagetti
Simona Biagetti
SCStefano Cascinu
Stefano Cascinu
Clinical observations suggested that a non negligible proportion of patients, ranging from 40% to 70%, does not seem to benefit from the use of anti-EGFR targeted antibodies even in the absence of a mutation of the K- RAS gene. The EGFR pathway activation via the Ras-Raf-MAP-kinase and the protein-serine/threonine kinase AKT could determine resistance to anti-EGFR treatment. We tested the interaction between phosphorylated AKT and MAPK expression in colorectal tumours and corresponding metastases and global outcome in K-RAS wild type patients receiving irinotecan-cetuximab. Seventy-two patients with histologically proven metastatic colorectal cancer, treated with Irinotecan and Cetuximab based chemotherapy, were eligible for our analysis. In metastases pAKT correlated with RR (9% vs. 58%, p = 0.004), PFS (2.3 months vs.9.2 months p < 0.0001) and OS (6.1 months vs.26.7 months p < 0.0001) and pMAPK correlated with RR (10% vs., 47%, p = 0.002), PFS (2.3 months vs.8.6 months p < 0.0001) and OS (7.8 months vs.26 months p = 0.0004). At multivariate analysis pAKT and pMAPK in metastases were able to independently predict PFS. pAKT in metastases independently correlated with RR as well pAKT and pMAPK expression in metastases may modulate the activity of EGFR-targeted antibodies. We could speculate that in patients with pAKT and pMAPK metastases expression targeting these factors may be crucial.

1 July 2012 in Digestive and Liver Disease
Verified
Journal Article
Closed access
Rossana BerardiRossana Berardi
Rossana Berardi
EMElena Maccaroni
Elena Maccaroni
AMAlessandra Mandolesi
Alessandra Mandolesi
GMGiovanna Mantello
Giovanna Mantello
AOAzzurra Onofri
Azzurra Onofri
SCStefano Cascinu
Stefano Cascinu

1 October 2013
Verified
Journal Article
Closed access
FNFrancesca Negri
Francesca Negri
CACinzia Azzoni
Cinzia Azzoni
LBLorena Ospedaliera Universitaria Bottarelli
Lorena Ospedaliera Universitaria Bottarelli
NCNicoletta Campanini
Nicoletta Campanini
AMAlessandra Mandolesi
Alessandra Mandolesi
AAAndrea Ardizzoni
Andrea Ardizzoni

7 May 2015 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
RGRiccardo Giampieri
Riccardo Giampieri
AMAlessandra Mandolesi
Alessandra Mandolesi
KAKhaled M Abouelkhair
Khaled M Abouelkhair
Cristian LoretelliCristian Loretelli
Cristian Loretelli
MPMichela Del Prete
Michela Del Prete
Mario ScartozziMario Scartozzi
Mario Scartozzi
The aim of our study was to evaluate whether a panel of biomarkers, prospectively analysed might be able to predict patients’ clinical outcome more accurately than RAS status alone. K-RAS (exons 2, 3, 4) wild type colorectal cancer patients, candidates to second/third-line cetuximab with chemotherapy were prospectively allocated into 2 groups on the basis of their profile: favourable (BRAF and PIK3CA exon 20 wild type, EGFR GCN ≥ 2.6, HER-3 Rajkumar score ≤ 8, IGF-1 immunostaining < 2) or unfavourable (any of the previous markers altered or mutated). After the introduction of N-RAS status (exons 2, 3, 4) only RAS wild type patients were considered eligible. Primary aim was response rate (RR). To detect a difference in terms of RR among patients with an unfavourable profile (estimated around 25%) and patients with a favourable profile (estimated around 60%), with a probability alpha of 0.05 and beta of 0.05, required sample size was 46 patients. Secondary endpoints were progression free survival (PFS) and overall survival (OS). Forty-six patients were enrolled. Seventeen patients (37%) were allocated to the favourable and 29 patients (63%) to the unfavourable profile. RR in the favourable and unfavourable group was 11/17 (65%) and 2/29 (7%) (p = 0.007) respectively. The favourable group also showed an improved PFS (8 months vs. 3 months, p < 0.0001) and OS (15 months vs. 6 months, p < 0.0001). Our results suggest that prospective selection of optimal candidates for cetuximab treatment is feasible and may be able to improve clinical outcome.

1 December 2009
Verified
Journal Article
Closed access
Mario ScartozziMario Scartozzi
Mario Scartozzi
IBItalo Bearzi
Italo Bearzi
AMAlessandra Mandolesi
Alessandra Mandolesi
EGEva Galizia
Eva Galizia
CPChiara Pierantoni
Chiara Pierantoni
SCStefano Cascinu
Stefano Cascinu